Hybrid Capture II Testing for High-Risk Human Papillomavirus DNA in the Follow-up of Women Treated for High-Grade Cervical Intraepithelial Neoplasia

2013 ◽  
Vol 17 (3) ◽  
pp. 308-314 ◽  
Author(s):  
Jeffrey H.J. Tan ◽  
Suzanne M. Garland ◽  
Sepehr N. Tabrizi ◽  
Elya E. Moore ◽  
Jennifer A. Danielewski ◽  
...  
2009 ◽  
Vol 124 (2) ◽  
pp. 381-386 ◽  
Author(s):  
Albertus T. Hesselink ◽  
Johannes Berkhof ◽  
Daniëlle A.M. Heideman ◽  
Nicole W.J. Bulkmans ◽  
Jurjen E.H. van Tellingen ◽  
...  

2021 ◽  
Vol 21 (4) ◽  
Author(s):  
Ellinor Östensson ◽  
Karen Belkić ◽  
Torbjörn Ramqvist ◽  
Miriam Mints ◽  
Sonia Andersson

2005 ◽  
Vol 91 (2) ◽  
pp. 188-192 ◽  
Author(s):  
Luís Otávio Sarian ◽  
Sophie Françoise Mauricette Derchain ◽  
Denise da Rocha Pitta ◽  
Liliana Aparecida Angelo Andrade ◽  
Sirlei Siani Moráis ◽  
...  

Aims and background The purpose of this study was to assess the association between highly-oncogenic types HPV DNA detection by Hybrid Capture II (HCII) and residual or recurrent high-grade cervical intraepithelial neoplasia (CIN 2 or 3) during the follow-up of women submitted to large loop excision of the transformation zone (LLETZ). Study design In this cohort study, 94 women submitted to LLETZ because of CIN 2 or 3 between March 2001 and September 2002 were followed up twice yearly until September 2003. Follow-up visits consisted of an interview regarding clinical, social and demographic characteristics complemented with gynecological examination with specimen collection for Pap test and HCII and colposcopy. Eighty-one patients attended the first visit (mean 4.8 months, range 3-6) and 75 the second visit (mean 10.9 months, range 7-17 months). McNemar's test to assess the variation of HPV DNA detection following LLETZ, odds ratios (OR) to evaluate the correlation between HPV DNA positivity and residual/recurrent CIN during follow-up, and logistic regression to assess the risk of residual/recurrent CIN were used. Results There was a strong and significant reduction in HPV detection after LLETZ ( P <0.001). HPV DNA detection was correlated with residual/recurrent CIN at the first (OR = 103.4; 95% CI 5.5 to 1961.2) and second (OR = 12.7; 95% CI 1.1 to 345.5) follow-up visits. Multivariate analysis showed HPV persistence as a stand-alone risk factor for residual/recurrent CIN (OR = 50.3; 95% CI 3.8 to 663.1). Conclusions High risk HPV DNA detection decreased substantially after CIN treatment with LLETZ, but HPV persistence was strongly correlated with residual/recurrent CIN.


Sign in / Sign up

Export Citation Format

Share Document